Consolidated statements of cash flows (Parenthetical) - EUR (€) € in Millions |
6 Months Ended | |||||
|---|---|---|---|---|---|---|
Feb. 10, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Apr. 30, 2025 |
|||
| Disclosure of detailed information about borrowings [Line Items] | ||||||
| Adjustments for non current financial assets and deferred tax expense | € 0 | € 48 | ||||
| Income tax paid | (925) | (1,355) | ||||
| Interest paid | (260) | (206) | ||||
| Interest received | 111 | 170 | ||||
| Dividends received from non-consolidated entities | 3 | 5 | ||||
| Cash and cash equivalents | 6,350 | |||||
| Net change in short-term debt and other financial instruments | [1] | 1,955 | 3,322 | |||
| Dynavax | ||||||
| Disclosure of detailed information about borrowings [Line Items] | ||||||
| Net change in short-term debt and other financial instruments | € (249) | |||||
| Commercial paper program in USA | ||||||
| Disclosure of detailed information about borrowings [Line Items] | ||||||
| Net change in short-term debt and other financial instruments | € 2,388 | € 3,353 | ||||
| Opella Business | ||||||
| Disclosure of detailed information about borrowings [Line Items] | ||||||
| Cash and cash equivalents | € 667 | |||||
| ||||||